Home/Biosimilar Atlas/Infliximab/Reliance Life Sciences infliximab

Reliance Life Sciences infliximab

Infliximab biosimilar developed by Reliance Life Sciences. Reference product Remicade.

Brands by market: Brand not published by CDSCO (India) ยท Commercial partner or holder: Reliance Life Sciences
FDAnot listed
EMAnot listed
CDSCOMar 2014permitted
EDEnot listed

Status by market

FDA

United States

Not listed by FDA.

EMA

European Union

Not listed by EMA.

CDSCO

India

Central Drugs Standard Control OrganisationApproved
Brand
Not published by CDSCO (INN only)
Holder or applicant
Reliance Life Sciences Pvt Ltd
Pathway
Similar Biologic, manufacture and marketing permission
Approved
Mar 2014
Application or permission
MF-61/2014; BULK-62/2014
Indications as licensed
RA, AS, PsA, psoriasis, Crohn's disease, UC
Presentations
100 mg lyophilised vial
Note
First infliximab biosimilar permitted in India.
Source
S014
EDE

United Arab Emirates

Not listed by EDE.

Chronology

Sources

All infliximab biosimilars

Planning infliximab biosimilar development?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Talk to a biosimilar regulatory consultant
Data current to September 2026.